Johnson & Johnson vs J.M. Smucker Company (The)
Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Orrville OH consumer foods (NYSE: SJM) at $8.7B FY2025 revenue (+7%); Uncrustables fastest-growing brand, Hostess ($5.6B acquisition 2023) integration challenge, Jif/Folgers/Café Bustelo portfolio competing with Kraft Heinz.
About
The J.M. Smucker Company is an Orrville, Ohio-based consumer packaged goods company — publicly traded on the New York Stock Exchange (NYSE: SJM) as an S&P 500 Consumer Staples component — manufacturing and marketing a portfolio of leading food and beverage brands across coffee, peanut butter, fruit spreads, frozen sandwiches, and sweet baked goods through approximately 8,500 employees, with fiscal year 2025 net sales of $8.7 billion (+7% year-over-year). J.M. Smucker's brand portfolio spans three segments: U.S. Retail Pet Foods (Milk-Bone dog treats, Meow Mix, 9Lives, Kibbles 'n Bits), U.S. Retail Coffee (Folgers, Café Bustelo, Dunkin' retail coffee), and U.S. Retail Consumer Foods (Smucker's jams and jellies, Jif peanut butter, Uncrustables frozen sandwiches, and the Hostess sweet baked snacks portfolio). The Hostess acquisition (November 2023, $5.6 billion) made Smucker the owner of America's most iconic sweet baked goods brands — Twinkies, Donettes, Ding Dongs, Ho Hos, and Hostess CupCakes — while presenting integration challenges as the sweet baked snacks category faces shelf-stable competition from private label and shifting consumer preferences. CEO Mark Smucker (grandson of founder Jerome Monroe Smucker who founded the company in 1897) leads the company's brand portfolio management strategy, with Uncrustables (frozen peanut butter and jelly sandwiches, the fastest-growing Smucker brand) and Café Bustelo (Spanish-language espresso-style coffee, growing with US Hispanic demographics) as the primary growth drivers.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.